ENPP7 and Cholestatic liver disease: Although not conclusive due to the number of the samples, alk-SMase activity appeared particularly high in cholestatic liver disease excluding primary sclerosing cholangitis (PSC) (2.83±1.4 nmol h−1 mg−1) and low in steatosis (0.41±0.1 nmol h−1 mg−1) and PSC (0.72±0.37 nmol h−1 mg−1).